Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779233 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT00779233: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00779233 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00779233, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability of the test formulation of Zidovudine 300 mg tablets with an already marketed reference formulation RETROVIR ® 300 mg tablets (GlaxoSmithKline), under fasted conditions in healthy male and female adult subjects.
Interventions
- DRUG Zidovudine tablets 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-09 |
| Est. Completion | 2004-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779233
The ClinicalTrials.gov registry entry for NCT00779233 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zidovudine tablets 300 mg is the first listed.
NCT00779233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779233 about?
NCT00779233 is a clinical study titled "Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions". The purpose of this study is to evaluate the relative bioavailability of the test formulation of Zidovudine 300 mg tablets with an already marketed reference formulation RETROVIR ® 300 mg tablets (GlaxoSmithKline), under fasted conditions in healthy male and female adult subjects.
What is the current status of trial NCT00779233?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2004-09. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00779233?
The interventions under investigation include: Zidovudine tablets 300 mg (DRUG).
Who is sponsoring clinical trial NCT00779233?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.